Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion criteria~1. Histologically confirmed differentiated or poorly differentiated thyroid cancer that is metastatic or unresectable~2. Patients refractory to radio iodine~3. Radiologic evidence of clinically relevant disease progression (as per RECIST 1.1)~4. Measurable disease (by RECIST Version 1.1 criteria)~5. ECOG performance status of ≤ 1~6. Adequate hematologic, renal and liver function~7. Negative serum pregnancy test in premenopausal women.~8. Signed informed consent~Main Non-Inclusion criteria~1. Other histological subtypes of thyroid tumors: anaplastic, medullary, lymphoma or sarcoma~2. Active CNS metastases~3. Prior chemotherapy. Patients treated previously with molecular targeted therapies could be included.~4. Severe, acute or chronic medical or psychiatric condition or laboratory abnormality which in the judgment of the investigator would make the patient inappropriate for entry into this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- gemcitabine -oxaliplatine combination (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).